Norman D. Schwartz - 01 Sep 2022 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role: Chairman, President, and CEO, Director, 10%+ Owner
Signature: /s/ Norman Schwartz
Issuer symbol: BIO
Transactions as of: 01 Sep 2022
Net transactions value: -$372,954
Form type: 4
Filing time: 06 Sep 2022, 14:10:23 UTC
Previous filing: 29 Aug 2022
Next filing: 07 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIO	Bio-Rad A Common Stock	Options Exercise	$0	+1,266	+0.3%	$0.000000	424,936	01 Sep 2022	Direct	F1
transaction	BIO	Bio-Rad A Common Stock	Tax liability	$372,954	-767	-0.18%	$486.25	424,169	01 Sep 2022	Direct
holding	BIO	Bio-Rad B Common Stock						12,858	01 Sep 2022	By Spouse	F2
holding	BIO	Bio-Rad B Common Stock						4,060,054	01 Sep 2022	By Blue Raven Partners, L.P.	F3
holding	BIO	Bio-Rad B Common Stock						331,647	01 Sep 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIO	Restricted Stock Units	Award	$0	+8,326		$0.000000	8,326	01 Sep 2022	Bio-Rad A Common Stock	8,326	$0.000000	Direct	F4, F5
transaction	BIO	Restricted Stock Units	Options Exercise	$0	-1,266	-25%	$0.000000	3,798	01 Sep 2022	Bio-Rad A Common Stock	1,266	$0.000000	Direct	F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of Class A common stock acquired on the vesting of restricted stock units.
F2	The reporting person disclaims beneficial ownership of these shares.
F3	The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4	Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F5	The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
F6	On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.